All In Biotech

Drug Trial Radar · NCT07896187

A Phase 1 Study of NCR201 in Parkinson's Disease Patients With Prior DBS

A Phase 1, Open-Label, Single-Arm, 3+3 Dose-Escalation Clinical Trial of NCR201 Injection in Patients With Moderate-to-Advanced Primary Parkinson's Disease Previously Treated With Deep Brain Stimulation

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Oct 2028

Study completion Nov 2031

Sponsor

Sponsor type
Industry
First posted
Oct 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1 clinical trial to evaluate the safety and tolerability of a new cell therapy called NCR201. The study will enroll adults with moderate-to-advanced primary Parkinson's disease who have previously undergone deep brain stimulation (DBS) surgery. NCR201 is an investigational cell therapy derived from hypoimmune human induced pluripotent stem cells (iPSCs). Participants will receive a one-time surgical injection of NCR201 directly into a specific brain region (the putamen) on both sides. The study will use a standard "3+3" design to test two different doses: a low-dose group (4 million cells per side) and a high-dose group (8 million cells per side). The primary goal of this study is to check for any severe, dose-limiting side effects within the first 8 weeks after surgery, and to determine the maximum tolerated dose or the recommended dose for future Phase 2 studies. Researchers will also look for any initial signs of clinical benefit. Participants will be closely monitored through regular safety and symptom assessments for up to 96 weeks, with an optional long-term safety follow-up lasting an additional 3 to 5 years.

Conditions

  • PARKINSON DISEASE (Disorder)
  • Cell Therapy
  • Human Induced Pluripotent Stem Cells
  • Deep Brain Stimulation
  • Phase 1 Clinical Trial
  • Dopaminergic Progenitor Cells

Interventions

  • NCR201Biological

    NCR201 is human induced pluripotent stem cell (iPSC)-derived hypoimmune dopaminergic progenitor cell injection. It is administered via single stereotactic putaminal injection at dose level of either 4x10\^6 cells per side or 8x10\^6 cells per side. Product specification: 2.4x10\^7 cells /0.3 mL per vial, stored and transported under 2-8℃.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse EventsTime frame: From the time of cell infusion up to 12 months after NCR201 transplantation
  2. Maximum Tolerated Dose (MTD) of NCR201Time frame: Within 12 months after NCR201 transplantation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.